| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
MALT1 (18q21) gene rearrangement by FISH : 1002730
MessagePlease provide most recent Pathology report.
Test Code
MDFCPCMALT1 or 1002730
Alias/See Also
Marginal Zone of MALT type
CPT Codes
88271x2, 88275
Instructions
Bone Marrow aspirate in a green top sodium heparin tube (2-3 mL) or Peripheral Blood in a green top sodium heparin tube (2-10 mL). Tissue also accepted.
Transport Container
Blood or Bone Marrow: Do not centrifuge. Paraffin embedded formalin fixed tissue that has been fixed in 10% neutral buffered formalin for at least 6 hours and no longer than 48 hours. Two unstained slides, with tissue of 4 microns in thickness are needed for processing, accompanied by a circled H & E clearly indicating the area to be examined.
Transport Temperature
Blood or Bone Marrow: Ambient temperature within 24 hours. Specimen can be refrigerated if not transported immediately. Do not freeze. Protect from heat with a cold pack. Paraffin embedded tissue block: Ambient or on ice pack in summer. Slides: Ambient.
Specimen Stability
Blood and Bone Marrow: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Paraffin embedded tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Paraffin embedded tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology
Fluorescence in situ hybridization (FISH)
Setup Schedule
Monday - Friday
Report Available
Up to 7 days
Limitations
Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug
Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement
Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement
Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
Reference Range
An interpretive report will be provided.
Clinical Significance
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) is an extranodal lymphoma composed of morphologically heterogeneous small B-cells and comprises 7-8% of all B-cell lymphomas and up to 50% of primary gastric lymphomas. Chromosomal translocations frequently seen in MALT lymphoma include t(11;18)(q21;q21) and t( 14;18)(q32;q21); both are associated with MALT1 (18q21) gene rearrangement.
These translocations result in deregulation of the MALT1 gene and are believed to aid in oncogenesis. The t(14;18) is most frequently found in MALT lymphomas of the parotid glands, skin, ocular adnexa: sites rare for the t(11;18) translocation. However, pulmonary and gastrointestinal MALT lymphomas show high frequencies of t(11;18) translocation. For gastric MALT-type lymphomas, t(11;18) is a clonal marker for resistance to Helicobacter pylori eradication therapy and antigen-independent growth.
These translocations result in deregulation of the MALT1 gene and are believed to aid in oncogenesis. The t(14;18) is most frequently found in MALT lymphomas of the parotid glands, skin, ocular adnexa: sites rare for the t(11;18) translocation. However, pulmonary and gastrointestinal MALT lymphomas show high frequencies of t(11;18) translocation. For gastric MALT-type lymphomas, t(11;18) is a clonal marker for resistance to Helicobacter pylori eradication therapy and antigen-independent growth.
Performing Laboratory
med fusion
